Free safety and evidence review
Review a peptide, GLP-1, TRT, or growth-hormone schedule before you call it a stack
Select therapies to separate approved label constraints, clinician-defined timing, FDA significant-risk concerns, and unapproved products. The output is a question list—not a protocol.
Inputs stay in your browser. PeakedLabs does not use these tools to diagnose, select treatment, recommend a dose, or interpret lab results.
Select therapies for an evidence-status and timing review
Selection does not imply endorsement. The tool never supplies a dose, stack, sequence, fasting window, or syringe conversion.
Method and sources
Private inputs, cited context
This tool organizes your selections into a plan or checklist without computing estimates. The sources below provide clinical and regulatory context; they do not validate a personalized treatment plan.
- 01FDA — Bulk substances that may present significant safety risks
Source for the category 2 classification and safety concerns shown for ipamorelin acetate and injectable GHK-Cu.
- 02FDA — Understanding risks of compounded drugs
Compounded drugs are not FDA-approved and are not pre-reviewed for safety, effectiveness, or quality.
- 03FDA — Concerns with unapproved GLP-1 drugs
Source for unapproved GLP-1 warnings and retatrutide/cagrilintide compounding status.
- 04Endocrine Reviews — The chronobiology of hormone administration
Supports the distinction between natural rhythms and formulation-specific hormone administration.
- 05DailyMed — Egrifta SV
Source for tesamorelin's label-defined once-daily use, narrow indication, reconstitution, and monitoring context.